敗血症性多臓器不全(<特集>多臓器不全とアフェレシス)

概要

論文の詳細を見る
Sepsis has become increasingly prevalent over the past several decades worldwide including in Japan. Despite advances in supportive therapy and the use of potent antibiotics, mortality rates of patients with severe sepsis have not impressively improved over the past 20 years. At present, sepsis is a major cause of death with a mortality up to 50% in intensive care units. Multiple organ failure (MOF) is a frequent complication of severe sepsis and septic shock contributing to the high mortality. Recently, various treatments including polymyxin B-immobilized fiber (PMX-F), fluconazole, selective inhibitor of group IIA secretory phospholipase A 2, recombinant human granulocyte colony-stimulating factor, drotrecogin alfa (activated) and recombinant tissue factor pathway inhibitor were reported. In this article, we introduce our recent papers regarding albuminuria, bone metabolism, MRSA infection and septic encephalopathy treated by PMX-F. In addition, we summarize recent reports about MOF including acute renal failure and the treatments of MOF.
日本アフェレシス学会の論文
2004-02-29